# Atrium Therapeutics, Inc.: overview RNA · Nasdaq · CIK 2093101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rna.md) · [Financials](/companies/rna/financials.md) · [Filings](/companies/rna/filings.md) · [Insiders](/companies/rna/insiders.md) Latest reported revenue: [$3.0m](/filings/0001193125-26-349488.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-349488). ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [1.6](/filings/0001193125-26-224243.md) | [3.8](/filings/0001193125-26-349488.md) | [19.6](/filings/0001193125-26-224243.md) | [3.0](/filings/0001193125-26-349488.md) | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | [(473.7%)](/filings/0001193125-26-224243.md) | [(334.4%)](/filings/0001193125-26-349488.md) | [(88.0%)](/filings/0001193125-26-224243.md) | [(752.9%)](/filings/0001193125-26-349488.md) | | Net margin | % | [(473.6%)](/filings/0001193125-26-349488.md) | [(334.8%)](/filings/0001193125-26-349488.md) | [(84.7%)](/filings/0001193125-26-349488.md) | [(672.0%)](/filings/0001193125-26-349488.md) | | Diluted EPS | $ per share | [(0.44)](/filings/0001193125-26-224243.md) | [(0.75)](/filings/0001193125-26-349488.md) | [(0.97)](/filings/0001193125-26-224243.md) | [(1.18)](/filings/0001193125-26-349488.md) | | Free cash flow | $m | [(11.1)](/filings/0001193125-26-224243.md) | [(12.2) d](/filings/0001193125-26-349488.md) | [(33.2)](/filings/0001193125-26-224243.md) | [(4.0) d](/filings/0001193125-26-349488.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rna/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Sessa Capital IM, L.P.](/funds/1595849.md) | 2026-06-30 | $20.2m | 1,500,000 | | Added +948,609 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $19.5m | 1,447,476 | | Added +242,185 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $11.3m | 840,600 | Put | Reduced −178,200 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.8m | 730,831 | | Added +103,962 | | [CRCM LP](/funds/1483234.md) | 2026-06-30 | $8.6m | 641,539 | | New +641,539 | | [CRCM LP](/funds/1483234.md) | 2026-06-30 | $8.6m | 641,539 | | New +641,539 | | [TIG Advisors, LLC](/funds/1358253.md) | 2026-06-30 | $7.6m | 561,533 | | Reduced −46,019 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $5.2m | 386,929 | | Added +67,098 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $4.6m | 345,481 | | Added +166,921 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $4.2m | 310,341 | | Reduced −39,609 | ## Recent filings [All 51 filings](/companies/rna/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-09 | 06:17 ET | [8-K/A](/filings/0001193125-26-418417.md) | 8.01 Other events | 0001193125-26-418417 | | 2026-10-08 | 06:52 ET | [8-K](/filings/0001193125-26-417402.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-417402 | | 2026-08-13 | 16:51 ET | [10-Q](/filings/0001193125-26-349488.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349488 | | 2026-08-13 | 16:50 ET | [8-K](/filings/0001193125-26-349482.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349482 | | 2026-07-14 | 17:14 ET | [8-K](/filings/0001193125-26-303393.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-303393 | | 2026-05-14 | 16:51 ET | [10-Q](/filings/0001193125-26-224243.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224243 | | 2026-05-14 | 16:50 ET | [8-K](/filings/0001193125-26-224238.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-224238 | | 2026-02-27 | 17:22 ET | [8-K](/filings/0001193125-26-083227.md) | 1.01 Entry into a material agreement; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-083227 | | 2026-02-26 | 16:50 ET | [8-K](/filings/0001193125-26-077105.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-077105 | ## Latest annual report No annual report is in coverage. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a40f9b77-a28f-4b31-b390-225d16e1bc28) ## About the filer - CIK: 2093101 - Tickers: RNA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 08:57 ET. No prices; not investment advice.